Marker Stock Based Compensation To Revenue from 2010 to 2024
| MRKR Stock | USD 3.89 0.09 2.26% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.25920704 | Current Value 0.25 | Quarterly Volatility 18.89222969 |
Check Marker Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marker Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 M, Interest Expense of 12.9 K or Selling General Administrative of 5.6 M, as well as many indicators such as Price To Sales Ratio of 13.9, Dividend Yield of 0.0 or PTB Ratio of 3.62. Marker financial statements analysis is a perfect complement when working with Marker Therapeutics Valuation or Volatility modules.
Marker | Stock Based Compensation To Revenue |
Latest Marker Therapeutics' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Marker Therapeutics over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Marker Therapeutics' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Marker Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Marker Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 16.07 | |
| Geometric Mean | 7.14 | |
| Coefficient Of Variation | 117.56 | |
| Mean Deviation | 9.65 | |
| Median | 14.96 | |
| Standard Deviation | 18.89 | |
| Sample Variance | 356.92 | |
| Range | 79.1241 | |
| R-Value | (0.20) | |
| Mean Square Error | 369.68 | |
| R-Squared | 0.04 | |
| Significance | 0.49 | |
| Slope | (0.83) | |
| Total Sum of Squares | 4,997 |
Marker Stock Based Compensation To Revenue History
About Marker Therapeutics Financial Statements
Marker Therapeutics shareholders use historical fundamental indicators, such as Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although Marker Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Marker Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Marker Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.26 | 0.25 |
Pair Trading with Marker Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marker Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Marker Stock
| 0.57 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.48 | SLS | Sellas Life Sciences | PairCorr |
| 0.32 | ERNA | Eterna Therapeutics | PairCorr |
| 0.31 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Marker Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marker Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marker Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marker Therapeutics to buy it.
The correlation of Marker Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marker Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marker Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marker Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.